J&J (JNJ) Faces $8M Verdict Over Talc Case; Stock Still Gains 4.66% YTD
Copyright: moovstock / 123RF Stock Photo
According to the jury, the plaintiff's illness arose from her decades-long use of Johnson & Johnson's talcum powder products. The jury found that J&J's talcum powder products contained asbestos and that a design defect in these products substantially contributed to Ms. Paluzzi's mesothelioma. They also found Johnson & Johnson negligent in the design of the powder and that this negligence substantially contributed to her illness. As a remedy, the jury awarded Ms. Paluzzi $8 million: $5 million for past pain and suffering and $3 million for future pain and suffering.
Despite the unfavorable ruling, Johnson & Johnson's stock is up 4.66% year to date as of June 19.
Johnson & Johnson (NYSE:JNJ) is a global healthcare company. It develops and sells pharmaceuticals, medical devices, and consumer health products. It operates through two major divisions, pharmaceutical and MedTech. Some of its key pharmaceutical products include Darzalex, Stelara, and Tremfya.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Biotech Stocks Screaming a Buy and 13 Best Software Stocks to Buy Now.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
DA Davidson Lifts Salesforce (CRM) to Neutral, Keeps $225 PT
Salesforce, Inc. (NYSE:CRM) is one of the . On August 15, DA Davidson upgraded the stock to Neutral from Underperform with an unchanged price target of $225. According to the firm, declining investor sentiment is appropriate for a business whose organic growth in its core is decelerating along with mounting competitive pressure. However, Starboard has increased its stake in Salesforce by 47% this quarter and 'another round of activist involvement may help the company correct course.' A professional trader working on a laptop in a busy stock exchange. Upgrading the stock, the firm said the 'challenges' are already priced in for Salesforce. 'We are upgrading our rating to NEUTRAL from Underperform and maintaining our $225 price target based on 18.5x our updated FY27 EPS estimate.' Salesforce, Inc. (NYSE:CRM) is a cloud-based CRM company that has gained popularity after it unveiled its AI-powered platform called Agentforce. While we acknowledge the potential of CRM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Bernstein Reaffirms Outperform on TSM, $249 PT Amid Rising Capex Trends
Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) is one of the On August 15, Bernstein SocGen Group analyst Mark Li reiterated an Outperform rating on the stock with a $249.00 price target. The firm's analysis is a reflection of TSMC's significant position in the semiconductor equipment market. Investors are paying close attention to TSM's spending plans as they impact semiconductor equipment stocks, the broader chip industry, and AI. Bernstein noted that a substantial portion of TSMC's capital expenditure is allocated to infrastructure and non-wafer-based equipment, such as packaging and testing technologies. The firm also noted how WFE-to-semiconductor ratio remains elevated due to on shoring trends and technological complexity. Recent data illustrates that capital expenditure per wafer is also rising more rapidly than previously anticipated. Moreover, TSMC's spending is deflationary while China's is inflationary. With the US pushing companies to bring production back home, it is unclear whether it will be as aggressive as China. 'TSMC is 15-25% of the global wafer fab equipment (WFE) market, but China is 30-40%, as a sizable part of TSMCs capex is for infrastructure & non-wafer-based equipment (e.g. for packaging & testing). 15-25% is consistent with TSMC being10-20% of their total revenue disclosed by AMAT & TEL & 30-40% by ASML. Technology complexity & onshoring trend will keep the overall WFE/semi ratio elevated if not higher. Recent data suggests capex per wafer is rising more rapidly than we thought. More importantly TSMCs deflationary but China is inflationary & much bigger. The US uses tariffs, etc. to push onshoring capacity but also grants exemptions. This motivates companies/countries to over-promise & under-deliver. Time will tell if the US will be as forceful as China to make the US as meaningful to WFE.' Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) manufactures and sells advanced chips used in artificial intelligence applications. While we acknowledge the potential of TSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
3 minutes ago
- Yahoo
Berkshire's UnitedHealth Bet Highlights Long-Term Confidence Despite Depressed Earnings
On Friday, high-profile investors Michael Burry and Warren Buffett took positions in UnitedHealth Group Inc. (NYSE:UNH). Warren Buffett's fund bought little more than 5 million shares, and Burry disclosed in 13F filings that he purchased call contracts against 350,000 shares of UnitedHealth. The holdings suggest Burry is betting on a sector turnaround, particularly as Medicare Advantage rates have exceeded expectations for 2026, and UnitedHealth's competitive positioning remains strong despite recent setbacks. Berkshire Hathaway's stake in UnitedHealth signals confidence but largely reinforces the consensus that earnings are currently depressed. Investors with a five-year horizon could benefit, though most still expect steady annual of America Securities (BofA) remains bullish, projecting earnings recovery by 2027, which could drive both upside in profits and valuation multiples. Analyst Kevin Fischbeck raised the price forecast from $290 to $325 on the better peer multiples, reaffirming the Neutral rating. For UnitedHealth, guidance is everything. The stock only works if the company delivers, particularly with upside on its medical loss ratio. BofA notes it's been over two years since a "United-type" quarter, but steady beats and raises could restore confidence in management and its grasp of healthcare trends. CMS will release 2027 Star Ratings in mid-October, determining how much UnitedHealth's Medicare Advantage business qualifies for the 5% quality bonus. With Medicare Advantage margins thin at 3–5%, ratings are a key driver of profitability. Recent drops at Humana Inc. (NYSE:HUM) and CVS Health Group Inc. (NYSE:CVS) underscore the risk. If UnitedHealth posts weaker scores, margin recovery could be pushed back to 2028, leaving it no better than peers. For UnitedHealth, the key focus is the 2027 Medicare Advantage (MA) rate update, due in February 2026. The 2026 update delivered the most significant increase in a decade, easing concerns about an unfriendly policy stance. The bigger risk lies in coding changes. With 2026 as the final year of the V28 phase-in, no extra cuts were applied, which improved sentiment. However, 2027 could pair a stronger rate update with a new coding adjustment (V29), potentially offsetting gains. Price Action: UNH stock is trading higher by 3.58% to $314.88 at last check Monday. Read Next:Photo by via Shutterstock Latest Ratings for UNH Date Firm Action From To Jan 2022 SVB Leerink Maintains Outperform Jan 2022 BMO Capital Maintains Market Perform Jan 2022 Raymond James Maintains Strong Buy View More Analyst Ratings for UNH View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? UNITEDHEALTH GROUP (UNH): Free Stock Analysis Report This article Berkshire's UnitedHealth Bet Highlights Long-Term Confidence Despite Depressed Earnings originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
